EAN: 9783319204321

COMBINATION THERAPY IN DYSLIPIDEMIA GEBUNDEN

Comprising contributions from leading lipidologists from around the world  this book presents
the latest and most comprehensive knowledge on the different options for combination therapy of
dyslipidemia and includes discussion of future therapies that are currently in late stages of
clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality
and most patients with this condition fail to achieve adequate control of their serum lipid
levels with monotherapy. However  recent US and European guideline recommendations  based on
randomized  controlled trials  fail to discuss combination therapy options for patients with
dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in
this book specifically examine the role of add-on therapy with different agents modulating the
different lipid fractions in the blood  e.g. bile acid sequestrants  fibric acid derivatives
(fibrates)  omega-3 fatty acids (fish oils)  inhibitors of Niemann-Pick C1 like 1 (NPC1L1)
protein  cholesteryl ester transfer protein (CETP)  apolipoprotein B-100 and microsomal
triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin kexin
type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy
options such as nutraceuticals  functional foods and lipoprotein apheresis. The book also
discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management
of cardiovascular risk in patents with dyslipidemia.

Aktuelle Preise zur EAN 9783319204321

Produktinformationen zur 9783319204321